ArticleFrontiers in medicine2025
Non-invasive prediction of EGFR gene mutations in non-small cell lung cancer by multi-parameter CT perfusion imaging.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quantitative PCCT spectral parameters for noninvasive prediction of EGFR status and its subtypes in lung adenocarcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: In current clinical practice, invasive methods such as biopsy are commonly used to obtain tumor tissues for epidermal growth factor receptor (EGFR) mutation detection in patients with non-small cell lung cancer (NSCLC). This study aimed to explore the underlying association between various quantitative parameters of CT perfusion imaging (CTPI) and EGFR mutation, thus providing a new auxiliary diagnosis basis for non-invasive prediction of EGFR mutation status in patients with NSCLC. Methods: Patients with a confirmed NSCLC diagnosis by surgery or biopsy were prospectively enrolled. All patients underwent pulmonary CTPI within 1 week before biopsy, as well as EGFR gene detection after biopsy, and were then divided into the EGFR mutation group and the wild-type group. Differences in quantitative parameters between the two groups were analyzed, and significant variables were identified for further construction of the predictive model. The receiver operating characteristic (ROC) curves were constructed, and the area under curve (AUC) was calculated to assess the predictive performance. Results: A total of 86 patients were included, including 45 women and 41 men. There were 47 cases in the mutation group and 39 cases in the wild-type group. A univariate analysis showed that compared with the wild-type group, blood volume (BV) (5.56 ± 1.51 vs. 3.04 ± 1.07, Conclusion: BV, TTP, and PS were independent predictors of EGFR mutation in patients with NSCLC. The combined CTPI parameter model (BV + TTP + PS) had the highest predictive performance and could be more reliable than any single parameter in clinical auxiliary diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.